BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35514022)

  • 1. Effect of Testosterone Replacement Therapy on Quality of Life and Sexual Function in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency: Results From a Randomized Double-blind Trial.
    Højer EG; Kreiberg M; Dehlendorff C; Jørgensen N; Juul A; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2022 Aug; 20(4):334-343. PubMed ID: 35514022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
    Kreiberg M; Jørgensen N; Juul A; Lauritsen J; Oturai P; Helge JW; Christensen JF; Aksglaede L; Schauer T; Wagner T; Rosenvilde J; Grunwald E; Dehlendorff C; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2022 Oct; 20(5):404-414. PubMed ID: 35701334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Kreiberg M; Oturai PS; Helge JW; Daugaard G
    BMC Cancer; 2017 Jul; 17(1):461. PubMed ID: 28673265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction.
    Skøtt JW; Lauritsen J; Kreiberg M; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2019 Feb; 17(1):e65-e71. PubMed ID: 30293923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency.
    Medici C; Jørgensen N; Juul A; Albrethsen J; Kreiberg M; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2024 Feb; 22(1):e106-e112.e4. PubMed ID: 37673783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
    Howell SJ; Radford JA; Adams JE; Smets EM; Warburton R; Shalet SM
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):315-24. PubMed ID: 11589674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
    Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
    Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
    Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testicular cancer survivors have shorter anogenital distance that is not increased by 1 year of testosterone replacement therapy.
    Priskorn L; Kreiberg M; Bandak M; Lauritsen J; Daugaard G; Petersen JH; Aksglaede L; Juul A; Jørgensen N
    Hum Reprod; 2021 Aug; 36(9):2443-2451. PubMed ID: 34223605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer.
    Bandak M; Lauritsen J; Johansen C; Kreiberg M; Skøtt JW; Agerbaek M; Holm NV; Daugaard G
    Eur Urol Focus; 2020 Jul; 6(4):711-719. PubMed ID: 30482585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction.
    Howell SJ; Radford JA; Smets EM; Shalet SM
    Br J Cancer; 2000 Feb; 82(4):789-93. PubMed ID: 10732747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions.
    Aydogan U; Aydogdu A; Akbulut H; Sonmez A; Yuksel S; Basaran Y; Uzun O; Bolu E; Saglam K
    Endocr J; 2012; 59(12):1099-105. PubMed ID: 22972022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
    Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors.
    Gerl A; Mühlbayer D; Hansmann G; Mraz W; Hiddemann W
    Cancer; 2001 Apr; 91(7):1297-303. PubMed ID: 11283930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study.
    O'Carrigan B; Fournier M; Olver IN; Stockler MR; Whitford H; Toner GC; Thomson DB; Davis ID; Hanning F; Singhal N; Underhill C; Clingan P; McDonald A; Boland A; Grimison P;
    Intern Med J; 2014 Aug; 44(8):813-7. PubMed ID: 25081047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial.
    Glintborg D; Vaegter HB; Christensen LL; Bendix E; Graven-Nielsen T; Andersen PG; Andersen M
    Eur J Endocrinol; 2020 Jun; 182(6):539-548. PubMed ID: 32213659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.